Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer
Ajjai Alva(Michigan Medicine), Pamela L. Paris(University of California, San Francisco), Tamara Huebner(University of Michigan), Cheryl Lee(Agency for Science, Technology and Research), Maha Hussain(Northwestern University), Gayatri Premasekharan(University of California, San Francisco), Cristian Ionescu‐Zanetti(Fluxion Biosciences (United States)), Christine Fu(Fluxion Biosciences (United States)), Terence W. Friedlander(University of California, San Francisco), Andrea Fan(Fluxion Biosciences (United States)), Tony Tran(Fluxion Biosciences (United States)), Melanie Clark(University of Michigan), Michael Schwartz(American Society of Clinical Oncology), Stephanie Daignault(University of Michigan), Brent K. Hollenbeck(University of Michigan), Khaled Hafez(University of Michigan), Alon Z. Weizer(University of Michigan)
Cited by 88
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k